AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.06 Increased By ▲ 0.02 (0.02%)
BOP 6.62 Decreased By ▼ -0.05 (-0.75%)
CNERGY 4.54 Increased By ▲ 0.03 (0.67%)
DCL 8.58 Increased By ▲ 0.03 (0.35%)
DFML 41.75 Increased By ▲ 0.31 (0.75%)
DGKC 87.40 Increased By ▲ 0.55 (0.63%)
FCCL 32.60 Increased By ▲ 0.32 (0.99%)
FFBL 65.00 Increased By ▲ 0.20 (0.31%)
FFL 10.23 Decreased By ▼ -0.02 (-0.2%)
HUBC 109.23 Decreased By ▼ -0.34 (-0.31%)
HUMNL 14.74 Increased By ▲ 0.06 (0.41%)
KEL 5.13 Increased By ▲ 0.08 (1.58%)
KOSM 7.56 Increased By ▲ 0.10 (1.34%)
MLCF 41.65 Increased By ▲ 0.27 (0.65%)
NBP 59.61 Decreased By ▼ -0.80 (-1.32%)
OGDC 193.00 Increased By ▲ 2.90 (1.53%)
PAEL 28.15 Increased By ▲ 0.32 (1.15%)
PIBTL 7.81 Decreased By ▼ -0.02 (-0.26%)
PPL 151.70 Increased By ▲ 1.64 (1.09%)
PRL 27.37 Increased By ▲ 0.49 (1.82%)
PTC 15.95 Decreased By ▼ -0.12 (-0.75%)
SEARL 86.02 Increased By ▲ 0.02 (0.02%)
TELE 7.75 Increased By ▲ 0.04 (0.52%)
TOMCL 35.59 Increased By ▲ 0.18 (0.51%)
TPLP 8.18 Increased By ▲ 0.06 (0.74%)
TREET 16.51 Increased By ▲ 0.10 (0.61%)
TRG 53.53 Increased By ▲ 0.24 (0.45%)
UNITY 26.25 Increased By ▲ 0.09 (0.34%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
BR100 9,998 Increased By 114.2 (1.15%)
BR30 31,214 Increased By 613.5 (2%)
KSE100 94,225 Increased By 869.6 (0.93%)
KSE30 29,197 Increased By 266.3 (0.92%)

Pfizer Inc will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical, marking the biggest deal by the cash-rich drugmaker since 2016 to beef up its portfolio ahead of patent losses for some cancer drugs.

The deal, announced on Tuesday, will give Pfizer access to Biohaven’s approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.

Flush with about $32 billion in cash on hand after its success with COVID-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.

Pfizer Q1 revenues jump 77% to $25.7bn on Covid-19 vaccine

The company also expects sales of its COVID-19 vaccines to drop from last year’s highs.

“Investors will like this deal. Given Pfizer’s strong balance sheet, this is still a small acquisition and we would expect more such deals,” Wells Fargo analyst Mohit Bansal said in a note.

The Biohaven deal is its largest since Pfizer’s $14 billion purchase of cancer drugmaker Medivation in 2016.

Pfizer will acquire all Biohaven shares that it does not already own for $148.50 per share in cash, a 78.6% premium to last closing price. It had taken a 2.6% stake in Biohaven in November.

Biohaven shares jumped 70.1% to $141.39 before the bell, while Pfizer was trading flat at $48.60.

With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly.

Biohaven’s rimegepant, sold as Nurtec ODT in the United States, is approved for use as both a treatment and preventative for migraines and is expected to bring in sales of over $4 billion by 2030. It brought in sales of $462.5 million in 2021.

Biohaven is also developing another CGRP inhibitor and testing two non-CGRP drugs in late-stage studies.

After the deal closes, Biohaven shareholders, including Pfizer, will get 0.5 of a share of a new publicly traded company that will retain Biohaven’s non-CGRP treatments.

Comments

Comments are closed.